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immunoregulationThe signiﬁcance of TLR expression and Tregs inHBV infection has not been clearly described. In this report,ﬂow
cytometry was performed to assess TLR2/4 expression onmonocytes and circulating CD4+CD25+CD127low/−
Tregs frequency of 16 acute hepatitis B (AHB), 42 chronic hepatitis B (CHB), 22 asymptomatic HBV carriers
(AsC), and 20 normal controls (NC).We found that TLR2 and TLR4were overexpressed on CD14+monocytes in
HBV-infected patients as compared with NCs. Upregulation of TLR2 in NCs and TLR4 in CHBs was observed
following HBeAg incubation. However, TLR2 and TLR4 expression decreased after HBcAg stimulation. The
difference in the proportion of Tregs between NCs and CHBs was signiﬁcant. Both Pam3Csk4 (TLR2 agonist)-
and lipopolysaccharide (TLR4 agonist)-activated CD4+CD25+Tregs showed enhanced suppression function in
CHBs. These results suggest that overexpression of TLR2 and TLR4 may modulate the suppressive function of
Tregs, which contribute to the immunotolerance of chronic HBV infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis B virus (HBV) is a hepatotropic DNAvirus that infects ~350
million people worldwide, with a particularly high prevalence in Asia
and Africa (Lok and McMahon, 2001). HBV infection in adults
frequently results in a self-limiting, acute hepatitis that confers
protective immunity and causes no further disease. In contrast, most
children fail to clear the virus, resulting in chronic infection. Most
chronically infected patients remain largely asymptomaticwithout life-
threatening liver disease, but 1–2millionpeople die annually due to the
consequences of chronic HBV infection, including liver cirrhosis and
hepatocellular carcinoma (Hoofnagle et al., 2007; Lok and McMahon,
2001). Patients often exhibited impairment of HBV-speciﬁc T cell
activity and failed to generate sufﬁcient cellular immunity against the
virus during chronic HBV infection (Chisari and Ferrari, 1995; Webster
et al., 2004). However, the precise mechanism associated with T cell
tolerance is still not completely understood due to the host range
limitations of HBV and the lack of small animal models.
With regard to the role of CD4+CD25+ regulatory T cells (Tregs) in
viral persistence, an abundanceof experimental datahas suggested that
CD4+CD25+ Tregs activities might represent the escape mechanisms
responsible for virus-induced immune modulation. During some virusll rights reserved.infections, CD4+CD25+ Tregs responses appear to cause viral persis-
tence and chronic infection, particularly in human immunodeﬁciency
virus (HIV) (Kinter et al., 2004) and hepatitis C virus (HCV) infection
(Boettler et al., 2005). According to more recently published data,
CD4+CD25+Tregs could contribute to a sustained stateof virus-speciﬁc
T cell collapse, which is characteristic of chronicHBV infection (Barboza
et al., 2007; Franzese et al., 2005; Kondo et al., 2006; Peng et al., 2008;
Stoop et al., 2005; Xu et al., 2006; Yang et al., 2007). However, the
mechanism for modulation of CD4+CD25+ Tregs functions during
chronic HBV infection remains obscure. Because Tregs are naturally
occurring, it is anticipated that the cellswouldbe strongly inﬂuencedby
innate immunity, including the activation of Toll-like receptors (TLRs)
(Liu et al., 2006a; Medzhitov, Preston-Hurlburt, and Janeway, 1997).
TLRs, which are commonly expressed on monocytes, play a crucial
role in early host defense. Activation of TLRs induces the expression of
some kinds of cytokines and chemokines, which control activation of
adaptive immune responses (Akira and Takeda, 2004). An abundance
of experimental data also suggested that alterations in TLRs by virus
might be responsible for virus-induced immunemodulation.Wu et al.
found that murine nonparenchymal liver cells can be activated by
TLR3 and TLR4 to produce interferon-β (IFN-β) and other mediators
that can potently suppress HBV replication (Wu et al., 2007).
Recent studies have demonstrated that the immunosuppressive
function of CD4+CD25+ Tregs can be modulated via TLR signaling.
Various pathways, including the direct effects of TLRs on CD4+CD25+
Tregs as well as the indirect route through antigen presenting cells and
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generation, expansion and function of CD4+CD25+ Tregs (Liu and
Zhao, 2007). Nevertheless, the effect of TLRs to CD4+CD25+ Tregs is
still somewhat controversial. TLR2, TLR4, and TLR8 is generally
thought to downregulate the function of Treg (Pasare and Medzhitov,
2003; Peng et al., 2005; Sutmuller et al., 2006). But new evidence also
suggested that LPS treatment increases the suppressive ability of
CD4+CD25+ Tregs, and LPS-activated CD4+CD25+ Tregs can efﬁ-
ciently control the occurrence of naïve CD4+ effector T cell-mediated
diseases (Caramalho et al., 2003). Because the ﬁndings of diffe-
rent studies have been contradictory, controversy remains as to
whether changes in the frequency and function of circulating TLRs,
CD4+CD25+ Tregs, and their interactions are correlated with HBV
clearance and persistence.
Data reported here suggest the following scenario. To establish a
chronic infection, HBV may make use of its antigens to change the
expression proﬁles of TLR2 and TLR4 onmonocytes. HBV antigens also
inﬂuence the frequency and function of CD4+CD25+ Tregs, whose
suppressive activity enhanced when exposure to TLR2 and TLR4
agonists, to contribute to immune dysfunction and account for viral
persistence. Our results therefore suggest a potential mechanism that
TLR2/4 signaling in regulating the adaptive immune response may
contribute to chronic HBV infection.
Results
Overexpression of TLR2 and TLR4 on monocytes from HBV-infected
patients
We examined peripheral blood monocytes from 42 patients with
HBeAg-positive chronic hepatitis B (CHB) 16 patients with acute
hepatitis B (AHB), 22 HBeAg-positive asymptomatic HBV carriers
(AsC), and 20 normal controls (NC). The clinical data obtained for the
enrolled subjects are listed in Table 1. Separate CD14-positive
populations of cells were gated by ﬂow cytometry (Fig. 1A). The
level of TLR2 and TLR4 expression was measured in these cell
populations, and a typical ﬂow histogram of CD14-positive TLR
expression is shown in Fig. 1B. Summary data from the enrolled
volunteers are shown in Fig. 1C.
Mean ﬂuorescence intensity (MFI) values corresponding to TLR2
were upregulated in AHB, CHB, and AsC groups compared with NC.
The MFI±standard deviation (SD) values were NC=96.79±16.84,
AHB=130.09±35.37, CHB=212.92±81.72 and AsC=161.13±
43.31. The MFI value evaluated for CHB patients was signiﬁcantly
increased compared to those of AHB patients (Pb0.001) and AsC
patients (P=0.011). A signiﬁcant difference was also observed
between AHB and AsC patients (P=0.017).
The MFI values corresponding to TLR4 were also increased in AHB,
CHB and AsC groups compared with NC. The MFI±SD values wereTable 1
Clinical characteristic of studied subjects.
Group AHB CHB
Case 16 42
Sex (males/female) 10:6 28:1
Age (years) 29.3±7.5 27.5
ALT (U/L) N400 (1222±679) N80
HBsAg positive 16 42
HBeAg positive 9 (56.25%) 42
HBeAb positive 7 (43.75%) 0
HBcAb positive 16 42
HBcAb IgM positive 16 0
HBV DNA positive 16 42
genotype B 5 13
genotype C 0 2
genotype B+C 11 27NC=19.73±5.44, AHB=28.07±5.39, CHB=24.74±8.17 and
AsC=28.96±5.29. The results revealed no signiﬁcant differences
between AHB and CHB and between AHB and AsC (PN0.05).
Inﬂuence of HBeAg and HBcAg on TLR2 and TLR4 expression
To explore whether TLR2 and TLR4 could be speciﬁcally affected by
HBV antigen in vitro, PBMCs from9ofNCs and14 of CHBswere cultured
for 20 h in RPMI 1640 supplemented 10% FBS, with or without
(untreated control) 2 μg/mL of puriﬁed HBeAg or 1 μg/mL of puriﬁed
HBcAg, and analyzed for co-expression of CD14 and TLR2/TLR4 by ﬂow
cytometry. Doses of 1 μg/mL, 2 μg/mL, 5 μg/mL, and 10 μg/mL were
tested for each antigen and optimal response was observed with 2 μg/
mL of puriﬁed HBeAg or 1 μg/mL of puriﬁed HBcAg. NC individuals did
not demonstrate signiﬁcant changes in either TLR2 (94.78±14.76 vs.
90.38±18.10, P=0.164) or TLR4 (17.05±6.70 vs. 16.05±7.23,
P=0.129) expression in response to HBcAg stimulation (Figs. 2A and
B). In contrast, Figs. 2C and D show that decreased expressions of TLR2
(155.79±37.63 vs. 128.06±23.81, P=0.0067) and TLR4 (23.11±3.93
vs. 19.51±3.52, P=0.0002) were observed in CHBs following HBcAg
incubation. Simultaneously, upregulation of TLR2 expression in NCs
(94.78±14.76 vs. 120.42±17.11, P=0.0039) and TLR4 expression in
CHBs (23.11±3.93 vs. 32.07±8.35, P=0.0001) were detected
following HBeAg stimulation. In contrast, No signiﬁcant differences in
TLR4 expression were noticed for NC individuals (17.05±6.70 vs.
23.40±12.37, P=0.074) or in TLR2 for CHBs (155.79±37.63 vs
171.81±41.27, P=0.153).
We subsequently studied the variation in CD14+, CD14+TLR2+,
and CD14−TLR2+ cells in the PBMC population. A representative
PBMC sample from CHBs analyzed by ﬂow cytometry is shown in Fig.
2E. Interestingly, after incubations for 20 h with HBeAg or HBcAg, the
proportions of CD14+ and CD14+TLR2+ cells in the PBMCs population
were signiﬁcantly decreased for both NCs and CHBs (Figs. 2F and G). A
signiﬁcant increase in CD14-TLR2+ cells was observed following
HBeAg stimulation, but neither NCs nor CHBs demonstrated signiﬁ-
cant differences in response to HBcAg (Fig. 2H).
Increased frequency of circulating CD4+CD25+CD127low/− Tregs in
CHB patients
We also analyzed peripheral blood from the volunteers described
above to determine the percentage of CD25+ T cells in the total CD4+ T
cell population. In CHB patients, the CD4+CD25+CD127low/− (ﬂuores-
cence intensity of CD127b102) population represented 3.93 to 8.76% of
CD4+ T cells; however, the total CD4+ CD25+ T cell population
comprised 6.60 to 28.87% of CD4+ T cells (Figs. 3A and B). As a result,
the frequency of CD4+CD25+CD127low/− Tregs was signiﬁcantly
higher in CHB patients (mean±SD: 6.00±1.24%) compared to NC
(mean±SD: 4.70±1.30%) (P=0.0048), but not compared to AHBAsC NC
22 20
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Fig. 1. Typical TLR proﬁles and expression on CD14+ peripheral blood monocytes obtained from control subjects and patients with HBV infection. (A) PBMCs from a representative
patient with CHB were separated using the gates shown by ﬂow cytometry. The larger gated population is made up of monocytes, while the smaller cells were lymphocytes.
Peripheral blood monocytes were stained with directly conjugated antibodies speciﬁc for CD14 and either TLR2 or TLR4. (B) Diagrams represent 10,000 CD14+ gated cells. The black
line represents expression of the isotype control, the blue line the control subject, the green line the AHB patient, the yellow line the AsC patient, and the red line the CHB patient. (C)
TLR2 and TLR4 expression on CD14+ monocytes in various subjects. The horizontal bars indicate the median level of TLR2 or TLR4. The individual expression level for each subject
included in the analysis is shown. Signiﬁcances of differences were calculated using the Dunn's multiple comparison test.
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SD: 5.42±1.35%) (P=0.45). Comparison of circulating CD4+CD25+
CD127low/− Treg frequencies among other groups revealed no
signiﬁcant differences (Fig. 3C). However, there was no signiﬁcant
difference in the frequency of the total CD4+CD25+ T cell population
between groups (Fig. 3D; P=0.073; Kruskal–Wallis H-test).
Factors related to TLR expression and Treg among CHB patients
To investigate whether the circulating TLR2/4 and CD4+CD25+
CD127low/− Tregs were correlated with the HBV replication level, we
measured the viral titers of serum from all tested HBV-infected
individuals. In CHB patients, Spearman analysis showed that TLR4
expression negatively correlated with the frequency of CD4+CD25+CD127low/− Tregs (r=−0.501, P=0.0007, Fig. 4A), but there was no
correlation between Tregs and serum copies of HBV DNA (r=0.243,
P=0.121, Fig. 4B).
HBV genotypes were determined by nested-PCR using type-
speciﬁc primers, as described previously (Naito, Hayashi, and Abe,
2001) for all enrolled HBV infected patients. Among the 80 patients,
24 (30%) were genotype B, 2 (2.5%) were genotype C and 54 (67.5%)
were mixed genotype B and C. No A, D, E, or F genotypes were found.
This is in agreement with the characteristic geographic distribution of
HBV genotypes in China. There were no signiﬁcant difference in ALT
values, positive rate of HBeAg, and HBV DNA value among the
different genotypes (data not shown). Among 42 of CHB patients, 13
(30.95%) were genotype B, 2 (4.76%) were genotype C, and 27
(64.29%) were mixed genotype B and C. For the different genotypes
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showed any signiﬁcant differences (Fig. 4C).
TLR2 and TLR4 enhance the suppression function of CD4+CD25+ Tregs
To investigate the effect of CD4+CD25+ Tregs on responder cells
and to determine the direct and indirect modulation of TLR2/4 on
CD4+CD25+ Tregs, PBMCs-Tregs (depletion of Tregs) and PBMCs-
Tregs + Tregs (depletion of Tregs and reconstituted Tregs at a ratio
of 1:1) were used as effector cells under stimulation with anti-CD3
or HBsAg, respectively. Both PBMCs-Tregs and PBMCs-Tregs + Tregs
proliferated strongly in response to anti-CD3 but a little weakly in
response to HBsAg stimulation. Adding CD4+CD25+ Tregs partially
suppressed (more than 20%) PBMCs proliferation stimulated by
both anti-CD3 and HBsAg (Fig. 5, lanes 1 and 2). When PBMCs-
Tregs were cocultured with Tregs which had been pretreated with
Pam3Csk4 (TLR2 agonist) and LPS (TLR4 agonist), cellular prolifer-
ation was signiﬁcantly decreased under both anti-CD3 and HBsAgFig. 2. Variations in TLR2 and TLR4 expression and proportions of CD14+, CD14+TLR2+, a
Wilcoxon matched pairs tests were used to assess TLR2 and TLR4 expression on CD14+ mon
typical PBMC sample from CHBs analyzed by ﬂow cytometry is shown in E. The proportion o
stimulation using Wilcoxon matched pairs tests.stimulation (Fig. 5, lanes 3 and 4). Furthermore, when PBMCs-Tregs
were pretreated with Pam3Csk4 and then cocultured with autolo-
gous Tregs, neither anti-CD3 nor HBsAg stimulation showed
signiﬁcant effects on cellular proliferation (Fig. 5, lane 6). Interest-
ingly, LPS-activated PBMCs-Tregs signiﬁcantly decreased cellular
proliferation when cocultured with Tregs stimulated by anti-CD3
but not by HBsAg (Fig. 5, lane 5).
Discussion
In the current study, we characterized the expression levels of
TLR2 and TLR4 proteins on CD14+ monocytes during acute and
chronic HBV infection and observed that monocytes from patients
with HBV infection expressed signiﬁcantly higher levels of TLR2 and
TLR4 proteins compared with those from normal controls, which
consistent with earlier data obtained for TLR2 and TLR4 expression on
hepatocytes from CHB patients (Guo, Wei, and Yang, 2007; Wei et al.,
2008). Because TLR2 and TLR4 were detected as both the importantnd CD14−TLR2+ cells in response to HBeAg and HBcAg stimulation in NCs and CHBs.
ocytes from NCs and CHBs following incubation with HBeAg or HBcAg for 20 h (A–D). A
f CD14+, CD14+TLR2+ and CD14-TLR2+ cells present in PBMCs (F–H) after HBV antigen
Fig. 2 (continued).
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recognition receptors, our works and others suggested that HBV
infection could modify the innate immune by upregulating the
expression of TLR2 and TLR4, which may also play an important role
in recognition and initiation of HBV infection.
In contrast to our ﬁndings, others (Chen et al., 2008; Riordan et al.,
2006; Visvanathan et al., 2007) reported that HBV downregulates the
expression of TLR2 on hepatocytes, Kupffer cells, and peripheral
monocytes, whereas the level of TLR4 expression did not signiﬁcantly
differ in response to HBV infection. To validate our results, we
investigated the postulate that the immunodysregulation of TLR2 and
TLR4 associated with HBV infection is partially mediated by
stimulation of HBV-encoded antigens. Puriﬁed HBcAg and HBeAg
were used to stimulate isolated PBMCs from NCs and CHBs, and their
effect on TLR2 and TLR4 expression was determined. We found that
TLR2 expression was increased by HBeAg induction in normal
individuals but no signiﬁcant changes were detected in CHBs. It is
known that pre-C/C mRNA is one of the ﬁrst transcripts to be
transcribed and translated following establishment of infection,
thereby making HBeAg as an early-phase viral protein product of
HBV infection in the serum (Yuh, Chang, and Ting, 1992). Therefore,
during the early phase of infection, HBeAg may function as a major
target for the inﬂammatory immune response and induce increased
expression of TLR2. Once chronic infection has been established, the
continual secretion of HBeAg may serve as the tolerogen, which is
necessary to maintain the tolerant state. Therefore, no TLR2 response
following HBeAg stimulation was detected in CHBs. Our results
indicate that HBeAg may function as both an immunogen (early stage
of infection) and a tolerogen (persistent infection) depending on the
context of HBV infection. Interestingly, we observed that following
either HBeAg or HBcAg incubation, the proportion percentages of
CD14+ and CD14+TLR2+ cells in PBMCs were decreased in both NCs
and CHBs. This may be due, in partly, to the toxicity of the puriﬁed
antigens. In our preliminary experiments, difference doses of antigens
were tested, and an optimal response was observed with 2 μg/mL of
HBeAg and 1 μg/mL of HBcAg, as a high dose of stimulus (10 μg/mL)
resulted in great cell death. Our results also reveal that TLR4 showedcontradictory expression proﬁles in response to HBcAg and HBeAg
during chronic HBV infection. This result has the remarkable
implication that an immunogenic difference between HBcAg and
HBeAg exists. In addition, we also determined the HBV genotypes of
the enrolled patients and found that the majority of them were
genotype B and C, differing from Oceania, which exhibits predomi-
nantly genotype A. We presumed that the differences between our
ﬁndings and those of others may be due to variations in geographic
location, viral subtypes and host genetic background.
Our study did not reveal a signiﬁcant difference in total CD4+
CD25+ T cells in the peripheral blood of HBV-infected patients.
Recently, it has been suggested that there is an inverse relationship
between the expression of Foxp3 and CD127, and in combination with
surface expression of CD25 it can distinguish between human
regulatory and conventional CD4+ T cells in human blood (Harti-
gan-O'Connor et al., 2007; Liu et al., 2006b). Latest study also showed
that 88.1–96.1% of CD25+CD127low/− T cells expressed Foxp3 in the
peripheral blood of gastric cancer patients (Shen et al., 2009). We
have used this information to analyze the Treg population within
total CD4+CD25+ T cells and show that a smaller population of
CD4+CD25+CD127low/− Tregs was signiﬁcantly increased in CHB
patients compared with healthy controls. Our data together with
those of others (Barboza et al., 2007; Franzese et al., 2005; Kondo
et al., 2006; Peng et al., 2008; Stoop et al., 2005; Xu et al., 2006; Yang et
al., 2007) imply that Tregs may be involved in the mechanism
responsible for viral persistence. Further analysis did not reveal a
positive correlation between the frequency of circulating CD4+CD25+
CD127low/− Tregs and the serum HBV DNA load. Those results are
identical to that reported by Franzese and Stoop (Franzese et al., 2005;
Stoop et al., 2005). It may indicate that the early stage infection (ﬁrst
few days/weeks after infection) really determining the total number
of Tregs and possible disease outcome. It is also possible that Tregs
accumulate and expand locally at the site of infection, where they
exert their suppressive activity (Cao et al., 2003; Yamazaki et al.,
2003). Another possibility is that a population of HBV-speciﬁc
regulatory cells that differ from CD4+CD25+CD127low/− Tregs
might be induced during chronic HBV infection, as in Barboza’s
Fig. 3. Frequency of circulating CD4+CD25+CD127low/− regulatory T cells (Tregs) in various subjects. (A) CD4+ T cells were separated into CD25+ and CD25− T cell subsets, and
CD4+CD25+CD127low/−Tregs were deﬁned by the ﬂuorescence intensity of CD25 and CD127 obtained using isotype control antibody. (B) Frequency of CD4+CD25+CD127low/− and
total CD4+ CD25+ T cells from chronic hepatitis B (CHB) patients. Data are expressed as box plots in which the horizontal lines represent the 25th, 50th, and 75th percentiles of the
measured frequencies of CD4+ CD25+ T cells and Tregs. (C) Percentages of CD4+CD25+CD127low/− Tregs in various subjects. The horizontal bars indicate the median percentage of
Tregs. The individual frequency for each subject included in the analysis is shown. Signiﬁcance of differences was calculated using the Dunn’s Multiple Comparison test. (D) The
percentage of total CD4+CD25+ T cells for the different groups.
39Y. Zhang et al. / Virology 397 (2010) 34–42study, a CD4+FoxP3+ IL-10-producing cell population in response to
HBcAg contribute to maintain active viral replication and subvert host
immune response (Barboza et al., 2007). In addition, virus may
potentially effects expression of these genes, since virus-speciﬁc
Tregs displayed a distinct phenotype and CD127 and CD25 ex-
pression deﬁnes CD4+ T cell subsets are differentially in HCV and
HIV infection (Dunham et al., 2008; Heeg et al., 2009). However,
measles virus infection in adults may not show this phenomenon
due to Yu’s study. Moreover, measles virus infection not only up-
regulates CD4+CD25+CD127low/− Tregs, but also induces IL-10-
producing CD14+ and CD4+CD25+ cells in PBMCs (Yu et al., 2008).
Further studies will determine whether monitoring the three subsets
of CD4+ T cells deﬁned based on the expression of CD25 and CD127
should be used in the clinical management of HBV-infected indi-
viduals and the levels of IL-10 expression should be determined in
these cells.
Recent study in autoimmune liver diseases (AILD) has focused on
the role of monocytes and their relationship with Tregs. Longhi et al.
(2009) found that monocytes were higher in number and expressed
higher levels of TLR4. Addition of Tregs in AILD enhanced monocyte
migration, magniﬁed TNF-alpha over IL-10 production and markedly
increased TLR4 expression levels. Monocyte overactivation and
inability of Tregs to restrain it may contribute to the loss of immune
tolerance and perpetuation of the autoimmune attack in AILD. We
observed that exposure of CD4+CD25+ Tregs to both TLR2 ligand
Pam3Csk4 and TLR4 ligand LPS could enhance the immunosup-
pressive function and decrease cellular proliferation in patients withCHB. These ﬁndings demonstrated that CD4+CD25+ Tregs may
respond directly to TLR2/4 signaling, a mechanism that is likely to
contribute to viral persistence and chronic HBV infection. In contrast,
increased inhibitory capability of CD4+CD25+ Tregs in response to
LPS-activated PBMCs-Tregs was found under non-speciﬁc anti-CD3
stimulation but not HBsAg-speciﬁc challenge. Preincubation of
PBMCs-Tregs with Pam3Csk4 did not affect the function of CD4+
CD25+ Tregs. These data suggested that indirect regulatory effects of
TLR2/4 on CD4+CD25+ Tregs may not take part in the immuno-
pathogenesis of chronic HBV infection. In a word, this direct immuno-
modulation pathway of TLR2/4 on CD4+CD25+ Tregs may therefore
provide potential applications in the treatment of CHB. Current data is
only shown at a 1:1 ratio, which would not occur in nature, however,
TLR2 and TLR4 has been proved to augment the functions of Tregs in
this study. Also, the speciﬁcity of TLRs agonists has not been fully
established and theymay have far reaching effects on the cells outside
of their TLR expression proﬁles. In addition, the in vitro study may not
have an in vivo equivalence. Thus, the mechanism of this interaction
requires further investigated in vivo and molecular mechanisms for
the regulation of CD4+CD25+ Tregs via TLRs also needs to clarify.
In summary, our ﬁndings demonstrate that patients with HBV
infection exhibited signiﬁcant up-regulation of TLR2 and TLR4 on
circulating monocytes. Exposure to HBeAg and HBcAg is able to
change the expression proﬁles of TLR2 and TLR4. Furthermore, a
marked increase in CD4+CD25+CD127low/− Tregs was observed in
the peripheral blood of CHB patients. Both Pam3Csk4 (TLR2
agonist)- and LPS (TLR4 agonist)-activated CD4+CD25+ Tregs
Fig. 4. Correlation analysis among Toll-like receptors (TLRs), regulatory T cells (Treg), and other factors in chronic hepatitis B (CHB) patients. Among the 42 CHB patients tested,
correlation between TLR4 expression and circulating CD4+CD25+CD127low/− Tregs (A), as well as between circulating CD4+CD25+CD127low/− Tregs and serum HBV DNA load (B)
were analyzed by Spearman correlation analysis. (C) TLR2, TLR4, and the frequencies of Tregs among different genotypes in CHB patients. The Kruskal–Wallis H test was performed
for comparison between groups.
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indicates a potentially important interaction between innate
immune responses and immunoregulation during HBV infection.
Further studies examining the mechanisms response for this
interaction in the context of HBV infection will be critical and
fruitful in guiding the development of new immunotherapeutics to
treat CHB.
Materials and methods
Subjects
Blood samples were collected from 80 HBV-infected patients,
including 16 patients with AHB, 42 patients with CHB, 22 of AsC. The
standards for diagnosesweremadeaccording to thediagnostic standard
of Chinese National Program for Prevention and Treatment of Viral
Hepatitis. All patients were hospitalized or followed-up in Tangdu
Hospital from May 2007 to June 2008. As a normal control, fresh blood
samples were obtained from 20 healthy age and sex matched
individuals. Patients who were co-infected with HIV, other hepatitis
viruses, and any bacterial infection or concurrently of afﬂicted by
immunocompromised diseases and autoimmune diseaseswere exclud-
ed. No patients received anti-HBV agents or immunomodulatory
treatments for 6 months before sampling. The study protocol was
approvedby the ethics committee of FourthMilitaryMedicalUniversity,
and written informed consent was obtained from each subject.
Virological assessment
HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were determined
by commercial enzyme immunoassay kits (Kehua Biotech, Shanghai,
China). Serum HBV DNA was quantitated using a commercial real-
time polymerase chain reaction (PCR) kit (PG Biotech, Shenzhen,
China), with detection limit threshold of 500 copies/mL. HBV
genotyping was performed as described previously (Naito, Hayashi,
and Abe, 2001).Isolation of peripheral blood monouclear cells (PBMCs) and CD4+CD25+
Tregs
PBMCs were isolated by Ficoll-Hypaque (Sigma-Aldrich, St. Louis,
MO) density gradient centrifugation. CD4+CD25+ Tregs were puriﬁed
using MagCellect Human CD4+CD25+ Regulatory T Cell Isolation Kit
(R&D systems, Huntingdon Valley, PA) according to the manufacturer's
instruction. The purity of enriched cells for CD4+CD25+ T cells (N90%)
was determined by ﬂow cytometry. Cells were incubated in RPMI 1640
(Hyclone, Logan, Utah) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen GIBCO, Grand Island, NY). PBMCs were
cultured (106/well) in 24-well plates with or without HBeAg (ViroStat,
Portland, ME; 2 μg/mL) or HBcAg (AbD Serotec, Oxford, UK; 1 μg/mL)
in different wells at 37 °C in a 5% CO2 environment.
Flow cytometric analysis
PBMCswere harvested by centrifugation at 300×g for 10min at 4 °C.
To stain TLR2 and TLR4, CD14-FITC (eBioscience, San Diego, CA), TLR2-
PE (eBioscience) and TLR4-APC (eBioscience) monoclonal antibodies
(mAbs) were utilized. To determine the frequencies of Tregs, mAbs
CD4-PerCP (BD Bioscience, San Jose, CA), CD25-FITC (BD Bioscience)
and CD127-PE (eBioscience) were used. Cells were incubated and
stained at 4 °C in the dark for 30 min. Samples were analyzed with a
four-color FACSCalibur analyzer (BD Biosciences Immunocytometry
Systems). Acquisitionswere performedwith CellQuest Pro software (BD
Biosciences Immunocytometry Systems) and analyses were performed
with FlowJo version 5.7.2 for Windows (Tree Star Inc., Ashland, OR).
Isotype control antibodies were used to separate positive and negative
cells in the PerCP, FITC, PE, and APC ﬂuorescence channels.
Suppression assay of CD4+CD25+ Tregs in response to TLR2 and TLR4
agonists
To evaluate the suppression activity, isolated CD4+CD25+ T cells
were cultured together with autologous PBMCs-Tregs at a ratio of 1:1
Fig. 5. Inhibitory capability of circulating CD4+CD25+ Tregs and TLR2/4 modulate on
CD4+CD25+ Tregs. Blood was sampled from 10 patients with CHB. PBMC-Treg
(depletion of Treg), PBMC-Treg+ Treg (depletion of Treg and add back Treg at a ratio of
1:1) were used as effector cells, respectively. The effector cells were inoculated in 96-
well plate at 100,000 cells per well, and stimulated by 10 μg/mL HBsAg or 1 μg/mL anti-
CD3 Ab. The effects of Pam3Csk4 (TLR2 agonist) and LPS (TLR4 agonist) on both Tregs
and PBMCs-Tregs were measured on cellular proliferation. Cells were cultured for 5
days. For the last 4 h, the cultures were pulsed with 10% of CCK-8. All data are shown as
the mean±standard deviation for 10 subjects in each group. The signiﬁcance of
differences was calculated using Dunn's multiple comparison test.
41Y. Zhang et al. / Virology 397 (2010) 34–42(5×104 cells, respectively), and stimulated with 1 μg/mL anti-CD3
(eBioscience) or 10 μg/mL HBsAg (AbD Serotec) in 96-well plates.
Beforemixture, Pam3Csk4 (InvivoGen, San Diego, CA) (400 ng/mL) or
LPS (InvivoGen) (100 ng/mL) were added to the culture medium of
CD4+CD25+ Tregs and PBMCs-Tregs, and the culture was maintained
for 24 h and then washed twice with PBS. For proliferation test, the
plate was cultured for 5 days, with replenishment of fresh medium
containing 20 U/mL recombinant human (rh) IL-2 (Sigma) at day 3.
Cellular proliferation was measured by Cell Counting Kit-8 (CCK-8,
Alexis Biochemicals, San Diego, CA). Brieﬂy, for the last 4 h culture, 20
μL (10% of the total volume) of CCK-8 solution were added to each
well. Wells that contained known number of viable PBMCs were also
prepared for creating a calibration curve. The absorbance of the
samples was measured at 450 nm using Model 680 Microplate Reader
(Bio-Rad, Hercules, CA).
Statistic analyses
Data were analyzed using SPSS version 13.0 for Windows. The
Kruskal–Wallis H test and Dunn's multiple comparison test were used
for comparison between groups. TheWilcoxonmatched pairs test wasused to compare TLRs expression before and after antigen stimulation.
Spearman correlation analysis was performed for correlation analysis.
A value of Pb0.05 was considered to indicate a signiﬁcant difference.
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